Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Proteon Therapeutics Inc.

www.proteontherapeutics.com

Latest From Proteon Therapeutics Inc.

Expedited Review Pathways: Three More Breakthroughs, Third RMAT Awarded

US FDA's popular breakthrough therapy designation given to Proteon's vonapanitase for dialysis patients, Synthetic Biologics' ribaxamase to prevent C. difficile infection, and River Vision's teprotumumab for thyroid eye disease; Vericel's cell therapy for heart failure is designated a regenerative medicine advanced therapy.

Review Pathway Regulation

Pipeline Watch: Phase III Misses For Fovista, Istradefylline And Vonapanitase

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Approvals Pipeline Watch

Proteon Therapeutics Slumps On Phase III Study Miss In CKD

Shares in Proteon Therapeutics lost nearly three-quarters of their value on news that its first Phase III trial for its lead product vonapanitase had failed. Undeterred, however, the company is increasing the size of its second pivotal study on the back of positive data from certain key endpoints.

Research & Development Clinical Trials

Execs On The Move, December 2015

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Renal System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Proteon Therapeutics Inc.
  • Senior Management
  • Timothy P Noyes, Pres. & CEO
    George A Eldridge, SVP, CFO
    Steven K Burke, MD, SVP, CMO
    Daniel P Gottlieb, VP, Corp. Dev.
    Scott Toner, SVP, Mktg.
  • Contact Info
  • Proteon Therapeutics Inc.
    Phone: (781) 890-0102
    200 West St.
    Waltham, MA 02451
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register